{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:53:26Z","timestamp":1791143606595,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008270","name":"Lantheus Medical Imaging Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007210","name":"Varian Medical Systems Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.eururo.2026.09.017","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:32:22Z","timestamp":1791055942000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["PSMA-PET\/CT-guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): 5-yr Analysis of a Phase 2 Randomized Controlled Trial"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6814-4439","authenticated-orcid":false,"given":"Colin","family":"Belliveau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Duplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guila","family":"Delouya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Taussky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maroie","family":"Barkati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Beauchemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Clavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Gauthier-Par\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levon","family":"Igidbashian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjory","family":"Jolicoeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thu-Van","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khun Visith","family":"Keu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean N.","family":"DaSilva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Juneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"M\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.09.017_b0005","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1200\/JCO-25-01553","article-title":"177Lu-prostate-specific membrane antigen neoadjuvant to stereotactic ablative radiotherapy for oligorecurrent prostate cancer (LUNAR): an open-label, randomized, controlled, Phase II study","volume":"43","author":"Kishan","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.09.017_b0010","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"Van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.09.017_b0015","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.09.017_b0020","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ajur.2020.02.001","article-title":"68Ga-PSMA PET\/CT versus CT and bone scan for investigation of PSA failure post radical prostatectomy","volume":"8","author":"Yuminaga","year":"2021","journal-title":"Asian J Urol"},{"key":"10.1016\/j.eururo.2026.09.017_b0025","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","article-title":"Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study","volume":"25","author":"Karpinski","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.09.017_b0030","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/S1470-2045(25)00339-0","article-title":"Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.09.017_b0035","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.eururo.2025.01.003","article-title":"The co-IMPACT consortium: integrating prostate-specific membrane antigen positron emission tomography and radiotherapy in prostate cancer care","volume":"87","author":"Murthy","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.09.017_b0040","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2025.3746","article-title":"Prostate-specific membrane antigen PET-guided intensification of salvage radiotherapy after radical prostatectomy: a Phase 2 randomized clinical trial","volume":"11","author":"Belliveau","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.09.017_b0045","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1186\/s13063-026-09709-0","article-title":"Platform for the Evaluation of innovations in Radiation oncology through registry-based conduct of multi-centric pragmatic randomized trials: PERa implementation","volume":"27","author":"Gigu\u00e8re","year":"2026","journal-title":"Trials"},{"key":"10.1016\/j.eururo.2026.09.017_b0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/cncr.23139","article-title":"The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer","volume":"112","author":"Abramowitz","year":"2008","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.eururo.2026.09.017_b0055","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1741-7015-8-18","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"2010","author":"Schulz","year":"2010","journal-title":"BMC Med"},{"key":"10.1016\/j.eururo.2026.09.017_b0060","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ijrobp.2022.12.055","article-title":"PSMA-PET\/CT-guided intensification of radiation therapy for prostate cancer (PSMAgRT): findings of detection rate, effect on cancer management, and early toxicity from a Phase 2 randomized controlled trial","volume":"116","author":"Petit","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2026.09.017_b0065","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/jlcr.3632","article-title":"Simplified and robust one\u2010step radiosynthesis of [18F]DCFPyL via direct radiofluorination and cartridge\u2010based purification","volume":"61","author":"Dornan","year":"2018","journal-title":"J Labelled Comp Radiopharm"},{"key":"10.1016\/j.eururo.2026.09.017_b0070","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12885-022-09283-z","article-title":"PSMA PET\/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial","volume":"22","author":"M\u00e9nard","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2026.09.017_b0075","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.euo.2018.09.010","article-title":"A systematic review on the role of imaging in early recurrent prostate cancer","volume":"2","author":"De Visschere","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.09.017_b0080","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11307-016-0957-6","article-title":"PSMA-based [18F]DCFPyL PET\/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer","volume":"18","author":"Rowe","year":"2016","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.eururo.2026.09.017_b0085","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.canlet.2021.05.014","article-title":"Aging of the progenitor cells that initiate prostate cancer","volume":"515","author":"Freeland","year":"2021","journal-title":"Cancer Lett"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826024139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826024139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:05:19Z","timestamp":1791140719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826024139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":17,"alternative-id":["S0302283826024139"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.09.017","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSMA-PET\/CT-guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): 5-yr Analysis of a Phase 2 Randomized Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}